SIGNAQUINE-200 Tablet is a trusted pharmaceutical formulation that contains Hydroxychloroquine Sulfate 200 mg, an antimalarial agent with established use in the treatment of autoimmune disorders and certain inflammatory diseases. It is widely recognized for its dual action—both as a disease-modifying antirheumatic drug (DMARD) and a preventive agent against malaria.
Hydroxychloroquine works by reducing the immune system's activity, thereby alleviating inflammation, swelling, pain, and joint damage in conditions such as rheumatoid arthritis and systemic lupus erythematosus (SLE). Additionally, its antimalarial mechanism disrupts the growth of Plasmodium species within red blood cells, making it suitable for both treatment and prophylaxis of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae infections.
Bluepill Express offers SIGNAQUINE-200 as part of its advanced third-party manufacturing services, complying with international quality benchmarks such as WHO-GMP, ISO, and DCGI certifications. This ensures not only consistent bioavailability and pharmacological effectiveness but also meets stringent regulatory standards required for global exports.
Manufactured with precision and stringent quality control protocols, SIGNAQUINE-200 undergoes thorough testing at every stage—from raw material sourcing to final product packaging. The tablets are manufactured using state-of-the-art machinery with strict environmental controls to preserve chemical stability, potency, and microbial safety.
SIGNAQUINE-200 is formulated to be well-tolerated and suitable for long-term therapy under medical guidance. It is offered in blister or bottle packs, customized according to client branding requirements, including multilingual packaging for regulatory acceptance in international markets. The packaging is secure, moisture-proof, and clearly labeled to maintain shelf-life and ensure patient safety.
Bluepill Express provides complete documentation support including Certificate of Analysis (COA), stability data, Certificate of Pharmaceutical Product (COPP), CTD dossiers, and country-specific registration assistance. The product is ideal for government tenders, private market distribution, and hospital procurement channels in regions such as Africa, Latin America, Asia-Pacific, and the Middle East.
While SIGNAQUINE-200 is generally safe, it should only be used under proper medical supervision due to potential side effects like gastrointestinal disturbances, visual changes, and rare cardiac concerns, particularly with prolonged use. As part of Bluepill Express’s commitment to transparency and global compliance, all relevant pharmacovigilance information is included with each shipment.
Description provided by bluepill express.
FIEO Registered
Export Ready
